ATE311872T1 - Zusammensetzungen und verfahren zum stimulieren von knochenwachstum - Google Patents

Zusammensetzungen und verfahren zum stimulieren von knochenwachstum

Info

Publication number
ATE311872T1
ATE311872T1 AT97954120T AT97954120T ATE311872T1 AT E311872 T1 ATE311872 T1 AT E311872T1 AT 97954120 T AT97954120 T AT 97954120T AT 97954120 T AT97954120 T AT 97954120T AT E311872 T1 ATE311872 T1 AT E311872T1
Authority
AT
Austria
Prior art keywords
post
substituted
compositions
methods
bone
Prior art date
Application number
AT97954120T
Other languages
English (en)
Inventor
Shirley R Gasper
Robert R West
Theresa Martinez
Nand Baindur
Kirk G Robbins
Virender M Labroo
Patricia A Mckernan
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE311872T1 publication Critical patent/ATE311872T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Pyrane Compounds (AREA)
AT97954120T 1996-12-13 1997-12-12 Zusammensetzungen und verfahren zum stimulieren von knochenwachstum ATE311872T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3289396P 1996-12-13 1996-12-13
PCT/US1997/023017 WO1998025460A1 (en) 1996-12-13 1997-12-12 Compositions and methods for stimulating bone growth

Publications (1)

Publication Number Publication Date
ATE311872T1 true ATE311872T1 (de) 2005-12-15

Family

ID=21867420

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97954120T ATE311872T1 (de) 1996-12-13 1997-12-12 Zusammensetzungen und verfahren zum stimulieren von knochenwachstum

Country Status (8)

Country Link
US (1) US6022887A (de)
EP (1) EP0944312B9 (de)
JP (2) JP4269015B2 (de)
AT (1) ATE311872T1 (de)
AU (1) AU729793B2 (de)
CA (1) CA2274789A1 (de)
DE (1) DE69734832T2 (de)
WO (1) WO1998025460A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990067010A (ko) * 1995-10-23 1999-08-16 오스테오스크린, 인코포레이티드 골결핍 상태의 치료용 조성물 및 그 치료방법
US6008208A (en) 1995-10-23 1999-12-28 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
US6376476B1 (en) * 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
JP2002507917A (ja) * 1997-07-04 2002-03-12 トルサナ オステオポロシス ダイアグノスティクス アクティーゼルスカブ 脊椎動物の骨質又は骨格状態を評価するための方法
WO1999008730A1 (en) * 1997-08-15 1999-02-25 Children's Medical Center Corporation Osteopontin coated surfaces and methods of use
US6410521B1 (en) * 1998-06-12 2002-06-25 Osteoscreen, Inc. Nutritional supplements for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6680307B1 (en) * 1998-12-04 2004-01-20 Roche Diagnostics Gmbh Use of ibandronate for promoting osseointegration of endoprostheses
US6403637B1 (en) * 1999-08-09 2002-06-11 Univ Saint Louis Methods of modulating matrix metalloproteinase activity and uses thereof
CA2385958A1 (en) * 1999-10-20 2001-04-26 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone and hair growth
WO2001037876A2 (en) * 1999-11-24 2001-05-31 Bayer Aktiengesellschaft Methods of ameliorating abnormal bone states
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
US8257737B2 (en) * 2001-08-09 2012-09-04 Giuseppe Intini Tissue implants and methods for making and using same
KR20030075715A (ko) * 2002-03-20 2003-09-26 학교법인 경희대학교 성장촉진활성을 갖는 로바스타틴, 이를 포함하는 약제학적조성물 및 이의 사용방법
US20040127563A1 (en) * 2002-03-22 2004-07-01 Deslauriers Richard J. Methods of performing medical procedures which promote bone growth, compositions which promote bone growth, and methods of making such compositions
US7041309B2 (en) * 2002-06-13 2006-05-09 Neuropro Technologies, Inc. Spinal fusion using an HMG-CoA reductase inhibitor
US20050271637A1 (en) * 2002-08-16 2005-12-08 Bodine Peter Van N BMP-2 estrogen responsive element and methods of using the same
US20040175366A1 (en) * 2003-03-07 2004-09-09 Acell, Inc. Scaffold for cell growth and differentiation
US20040176855A1 (en) * 2003-03-07 2004-09-09 Acell, Inc. Decellularized liver for repair of tissue and treatment of organ deficiency
US20040254238A1 (en) * 2003-04-07 2004-12-16 Osteoscreen Bone growth stimulation with NO/statin and other NO modulating combinations
CA2530490A1 (en) 2003-06-25 2005-01-13 Stephen F. Badylak Conditioned matrix compositions for tissue restoration
WO2005094553A2 (en) * 2004-03-24 2005-10-13 Doctor's Research Group, Inc. Compositions for promoting bone growth and methods thereof
US20070166360A1 (en) * 2004-03-31 2007-07-19 Kowa Co., Ltd. External preparation
US8129346B2 (en) 2004-04-15 2012-03-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
US20080200425A1 (en) * 2007-02-16 2008-08-21 Kurtz Seymour J Methods and compositions for regulating bone mineral density
US9474774B2 (en) * 2010-01-04 2016-10-25 Food Industry Research And Development Institute Pyridine alkaloids, preparation process thereof, and the uses of the pyridine alkaloids
WO2014030132A2 (en) 2012-08-22 2014-02-27 Universidad De Los Andes Use of statins for periodontal disease and bone regeneration
EP3133149B1 (de) * 2014-04-18 2022-06-22 Kyoto Prefectural Public University Corporation Verfahren zur herstellung von osteoblasten und osteoblasteninduktor
JPWO2020196463A1 (de) * 2019-03-28 2020-10-01
WO2023021514A1 (en) * 2021-08-18 2023-02-23 Orthotreat Ltd. Composition of β-caryophyllene and a statin, and methods of using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316765A (en) * 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
US5258376A (en) * 1989-11-22 1993-11-02 Bernstein Lawrence R Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones
JPH04269015A (ja) * 1991-02-25 1992-09-25 Nec Corp 故障回線救済制御方式
JPH05163150A (ja) * 1991-05-13 1993-06-29 E R Squibb & Sons Inc アテローム性動脈硬化症の抑制・治療剤
TW215434B (de) * 1992-03-07 1993-11-01 Hoechst Ag
PT642341E (pt) * 1992-05-13 2001-01-31 Us Health Utilizacao de inibidores de redutase de 3-hidroxi-3-metilglutaril coenzima a no tratamento de cancro
DE69403541T2 (de) * 1993-02-05 1997-09-25 Teijin Ltd Lacton-Verbindung und Verfahren zu ihrer Herstellung
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5545661A (en) * 1995-05-16 1996-08-13 Eli Lilly And Company Methods for inhibiting bone loss with bis-pyrone oxovanadium compounds

Also Published As

Publication number Publication date
CA2274789A1 (en) 1998-06-18
EP0944312B9 (de) 2006-07-05
JP2001506635A (ja) 2001-05-22
DE69734832T2 (de) 2006-08-31
EP0944312A4 (de) 2002-06-12
AU5798198A (en) 1998-07-03
WO1998025460A1 (en) 1998-06-18
JP4269015B2 (ja) 2009-05-27
EP0944312A1 (de) 1999-09-29
EP0944312B1 (de) 2005-12-07
AU729793B2 (en) 2001-02-08
US6022887A (en) 2000-02-08
DE69734832D1 (de) 2006-01-12
JP2008044956A (ja) 2008-02-28

Similar Documents

Publication Publication Date Title
ATE311872T1 (de) Zusammensetzungen und verfahren zum stimulieren von knochenwachstum
HUT77925A (hu) Dihidrobenzofuránok, azokat tartalmazó gyógyászati készítmények és eljárás előállításukra
NO992821L (no) Ketobenzamider som calpain-inhibitorer
CY1110240T1 (el) Νεα παραγωγα 2η-πυριδαζινο-3-ονης, φαρμακευτικες συνθεσεις που τα περιεχουν και μεθοδος για την παρασκευη του δραστικου συστατικου
HUT70541A (en) Adhesion receptor antagonists, pharmaceutical compositions comprising them and process for their preparation
WO2001052829A3 (en) Statin-type bone growth stimulators
BG103190A (en) Substituted pyrimidine derivatives and their pharmaceutical application
BR0111596A (pt) Composto e seu uso, processo para sua produção, composição farmacêutica e processo e método para prevenir ou tratar doenças
ES2056190T3 (es) Derivados de 4(4-fenil-1-piperazinil)fenoles, inhibidores de 5-lipoxigenasa.
TR199900920T2 (xx) Nafthiridin t�revleri.
BG104544A (en) Novel acylguanadine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists
ATE191473T1 (de) 2,3,5-trimethyl-hydroxyanilid-derivative, ihre herstellung und ihre theraoeutische verwendung
TR199701645A2 (xx) Vitronektin resept�r antagonistleri,bunlar�n imalat� ve kullan�m�
ES8407471A1 (es) Procedimiento para preparar derivados de prolina disustituidos
EP1109548A4 (de) Zusammensetzungen und verfahren zur behandlung und vorbeugung von knochenkrankheiten unter verwendung von tocotrienole
FI973221A0 (fi) 1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina
YU29300A (sh) Katalizovane reakcije prelaznog metala bazirane na hiralnim amin oksazolinil ligandima
NO884523D0 (no) Joderte polymerer, fremgangsmaate for deres fremstilling og deres anvendelse som kontrastmidler.
BG104232A (bg) Заместени 1,2,3,4,5,6-хексахидро-2,6-метано-3-бензазоцин- 10-оли, метод за тяхното получаване и приложението им като лекарствени средства
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
DE3773597D1 (de) 1,4-dihydropyridinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
DE69725167D1 (de) N-benzolsulfonyl-l-prolin derivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung
DE69609870D1 (de) 17beta-(2-oxo-tetrahydrofuran-4-yl)-thio-androstane derivate (17beta-(gamma-buttersäure-lacton)-thio derivate) zur behandlung von entzündungen, pharmazeutische präparate davon und ein verfahren zu ihrer herstellung
MY133140A (en) N-substituted azabicycloheptane derivatives, their preparation and use
EA200001157A2 (ru) Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties